All News

EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.

Read Article
lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
EULAR flags

Updates in SLE and APS

2026 EULAR Press Release

Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets.

Read Article
holding hands together support frail

New biomarkers in RA: Who to treat, Who to watch, Who to taper?

Aurelie Najm, MD, PhD

Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.

Read Article
#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

Janet Pope Janetbirdope ( View Tweet)

5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264

Janet Pope Janetbirdope ( View Tweet)

Is there enough data to recommend #rituximab For #ILD in #rheumatoid #arthritis @RheumNow #EULAR2026

Janet Pope Janetbirdope ( View Tweet)

And now does MRI do better than US at predicting RA progression in at risk pts? Short answer: No likely too sensitive! 130 anti-CCP+ symptomatic pts 36.9% progressed BL US positivity predicted progression HR 2.8 MRI showed prevalence of subclinical disease synovitis >80%

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can AI spot RA inflammation from a thermal hand scan? Cohort 100 RA pts AI model analysing thermal images detected US PD+ wrist inflammation AUC 0.87 Main features wrist temperature & heat-pattern With all due validation could this be the next mass screening tool for RA? https://t.co/2AzXj5yQJI

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
No big surprise here, deucravacitinib does as well without MTX Pooled analysis of 52wk data of POETYK PSA Same ACR20/50/70 and MDA response profiles also similar safety profiles #POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
A biomarker for CV disease in RA? Anti-CXCR3 antibodies asso w/ atherosclerosis Confirmed in a validation cohort Adding Ab profile to the mSCORE increases AUC from 0.6 to 0.9 Sens from 30 to 69% How does it compare with other ways of detecting atherosclerosis? #POS0899 https://t.co/O7bsLrVyzo

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis? 👉 DAPSA44 ✔️Good construct validity ✔️ High discriminatory capacity From the ASAS-Sparadise study #EULAR2026 @RheumNow https://t.co/Jbdvpn95jE

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can we finally personalize MTX dosing in #RA? liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (n=59): MTX-PG3 levels ↑ with dose and age, ↓ with higher disease activity and concomitant biologics. Route (oral vs SC) didn't matter. @RheumNow #EULAR2026 POS0251

Jiha Lee JihaRheum ( View Tweet)

SPARTAN-SSR: New quantitative criteria: BME in ≥3 consecutive slices OR any two of (BME, Erosion, Fat lesion each in ≥3 SIJ quadrants) or ankylosis in ≥3 halves achieves 88-96% sensitivity and 90-98% specificity across 3 cohorts. Precision #axSpA imaging. Abstr OP0100

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

#proof of #concept in #Sjogren’s #dis #lanalumab Treatment reduced in #SjD ✅reduced B cells in #salivary #glands —nearly complete depletion in serum ✅reduced B cell activation ✅improved #inflammation of #parotid & #submandibular glands @RheumNow #EULAR2026 #OP0163 #POS0284

Janet Pope Janetbirdope ( View Tweet)

OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB

Links:

TheDaoIndex KDAO2011 ( View Tweet)

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×